Fairvalue-Calculator Fairvalue-Calculator
EN DE

XTL Biopharmaceuticals Ltd (XTLB) Fair Value & Analysis

Healthcare · US · Market cap $6.6M

Price$2.57
Fair Value$1.54
Upside-40.0%
Quality92/100
Evidence: Low Range $1.15 – $2.30

Fair value as of: Jun 25, 2026

Analysis

XTL Biopharmaceuticals Ltd (XTLB) currently trades at $2.57, while our model-based Fair Value estimate is $1.54 — implying the stock looks roughly 40.0% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is XTL Biopharmaceuticals Ltd (XTLB) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.54 versus a price of $2.57 — about −40% (overvalued). Model-based estimate, not financial advice.
What is the fair value of XTLB?
Our 21-model fair value for XTL Biopharmaceuticals Ltd is $1.54 (as of Jun 25, 2026), built from audited fundamentals. The current price is $2.57.
What is the quality score of XTLB?
XTL Biopharmaceuticals Ltd has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.